Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOPURIN vs AMNESTROGEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LOPURIN is a brand name for allopurinol, a xanthine oxidase inhibitor. It reduces uric acid production by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.
Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription and promoting development and maintenance of female reproductive tissues and secondary sex characteristics.
Gout prophylaxis,Management of hyperuricemia in patients with cancer undergoing chemotherapy,Prevention of recurrent calcium oxalate calculi in patients with hyperuricuria
Treatment of moderate to severe vasomotor symptoms due to menopause,Treatment of vulvar and vaginal atrophy due to menopause,Prevention of postmenopausal osteoporosis,Estrogen replacement therapy in female hypogonadism,Palliative treatment of advanced breast cancer in selected postmenopausal women,Palliative treatment of advanced prostate cancer
200-600 mg orally once daily, typically starting at 300 mg/day and adjusting based on serum urate levels.
1 tablet (2.5 mg estradiol and 0.625 mg norgestimate) orally once daily
Allopurinol: 1-2 hours; oxypurinol: 18-30 hours (renal function dependent). Accumulation in renal failure; half-life of oxypurinol may exceed 100 hours in ESRD.
Terminal elimination half-life is 13-18 hours; steady-state achieved after 5-7 days.
Primarily hepatic via aldehyde oxidase to oxypurinol (alloxanthine), which is also active; minor metabolism by xanthine oxidase.
Hepatic metabolism via cytochrome P450 enzymes (CYP3A4 and others); undergoes enterohepatic recirculation.
Renal (primarily as unchanged drug and active metabolite oxypurinol): ~70% urinary excretion; remainder biliary/fecal. Dose adjustment required in renal impairment.
Primarily renal (90-95%) as glucuronide and sulfate conjugates; biliary/fecal elimination accounts for <5%.
Allopurinol: <1%; oxypurinol: ~20% (primarily to albumin). Negligible displacement interactions.
98% bound primarily to albumin and sex hormone-binding globulin (SHBG).
Allopurinol: ~1.6 L/kg; oxypurinol: ~0.6 L/kg. Indicates extensive tissue distribution, including renal and hepatic tissues.
1.0-1.5 L/kg; indicates extensive tissue distribution and binding.
Oral allopurinol: ~80% (mean); conversion to oxypurinol reduces systemic availability of parent drug. Food delays absorption but does not affect extent.
Oral: 2-10% due to first-pass metabolism; IM: 100%; Transdermal: 5-15%; Vaginal: 5-25%.
For GFR 10-20 m L/min: 200 mg/day; GFR <10 m L/min: 100 mg/day or avoid use; consider alternative in severe impairment.
No specific dose adjustment required; use with caution in severe impairment (e GFR <30 m L/min/1.73m²) due to potential fluid retention
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce by 75%.
Contraindicated in Child-Pugh class B and C; for class A, use lowest effective dose with monitoring
Children 6-10 years: 100 mg orally once daily; 11-16 years: 200-300 mg orally once daily; adjust based on serum urate.
Not indicated for pediatric use; safety and efficacy not established
Start at lower end of dosing range (100-200 mg/day) due to age-related renal decline; monitor renal function and urate levels.
Use lowest effective dose for shortest duration; increased risk of stroke, dementia, and breast cancer; consider alternative therapies
No FDA black box warning.
Estrogens increase the risk of endometrial cancer in postmenopausal women with an intact uterus. Estrogen-progestin therapy increases the risk of cardiovascular events, breast cancer, and probable dementia. Estrogen-alone therapy increases the risk of stroke and deep vein thrombosis.
Hypersensitivity syndrome (DRESS) may occur; discontinue at first sign of rash,Acute gout flares may occur upon initiation; prophylactic colchicine or NSAIDs recommended,Renal impairment requires dose adjustment; increase doses cautiously,Monitor liver function; hepatotoxicity reported,Bone marrow suppression (leukopenia, thrombocytopenia) may occur,Anticoagulant effect of warfarin may be enhanced
Cardiovascular disorders (stroke, MI, thromboembolism), malignant neoplasms (endometrial cancer, breast cancer), probable dementia (use >65 years), gallbladder disease, hypercalcemia, visual abnormalities, elevated blood pressure, hereditary angioedema, hypertriglyceridemia, fluid retention, hypothyroidism, exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, SLE, hepatic hemangiomas, and conditions aggravated by fluid retention.
Hypersensitivity to allopurinol or any component,Concurrent use with azathioprine or mercaptopurine unless dose reduction is implemented
Known or suspected pregnancy, undiagnosed abnormal genital bleeding, known or suspected breast cancer (except selected patients), known or suspected estrogen-dependent neoplasia, active DVT/PE or history of thromboembolic disorders, known protein C, protein S, or antithrombin deficiency, known thrombophilic disorders, active or recent arterial thromboembolic disease (e.g., stroke, MI), known liver impairment or disease, known hypersensitivity to any ingredient.
Avoid high-purine foods (organ meats, sardines, anchovies, shellfish, red meat). Limit alcohol intake, particularly beer and spirits. Maintain adequate hydration. No significant food-drug interactions reported.
Grapefruit and grapefruit juice may increase estrogen levels; avoid large amounts. No significant food interactions reported but take with or without food consistently to maintain stable absorption.
FDA Pregnancy Category D. First trimester: risk of congenital heart defects, cleft palate, and hypospadias based on animal studies and limited human data. Second and third trimesters: risk of fetal renal dysfunction, oligohydramnios, and neonatal renal impairment due to fetal renin-angiotensin system suppression.
First trimester: Increased risk of congenital anomalies including cardiovascular defects and neural tube defects. Second and third trimesters: Risk of urogenital tract abnormalities, feminization of male fetus, and potential long-term reproductive effects. Use contraindicated in pregnancy.
Small amounts of LOPURIN are excreted in breast milk. M/P ratio is approximately 0.2. The American Academy of Pediatrics considers the drug compatible with breastfeeding, but caution is advised due to potential for infant renal effects. Monitor infant for hypotension and renal function.
Contraindicated during breastfeeding. Amnestrogen is excreted in breast milk; M/P ratio unknown. Potential for serious adverse effects in nursing infants including hormonal disruption.
Increased plasma volume during pregnancy may reduce concentrations; dose adjustments are not routinely recommended due to variable pharmacokinetics. However, if blood pressure control is inadequate, consider increasing the dose under close monitoring. Postpartum, reduce dose to prepregnancy level to avoid hypotension.
Not applicable as drug is contraindicated in pregnancy. No dose adjustment recommended due to avoidance of use.
Allopurinol is a xanthine oxidase inhibitor. Initiate at low dose (100 mg/day) and titrate to reduce risk of gout flares. Monitor for hypersensitivity reactions, especially in renal impairment. Doses must be adjusted for renal function (Cr Cl <60 m L/min). Do not use with azathioprine or 6-mercaptopurine without dose reduction of cytotoxic agents. Avoid restarting after severe hypersensitivity.
Amnestrogen (estrogen-progestin combination) is used for hormone replacement therapy. Monitor for thromboembolic events; avoid in patients with history of DVT/PE. Use lowest effective dose for shortest duration. Not for use in pregnancy; contraindicated in breast cancer. May increase risk of endometrial cancer if used without progestin in women with intact uterus.
Take after meals to reduce GI upset.,Drink plenty of fluids (2-3 liters/day) to prevent kidney stones.,Report any rash, itching, or swelling immediately as these may signal a serious allergic reaction.,Do not stop medication abruptly; gout flares may occur during early treatment.,Avoid alcohol, especially beer, as it can increase uric acid levels.,Keep regular appointments for blood tests to monitor uric acid and kidney function.
Take exactly as prescribed; do not skip doses.,Report immediately any signs of blood clots: sudden leg pain, chest pain, shortness of breath, or vision changes.,Avoid smoking while on this medication; increases clot risk.,Do not use during pregnancy; if pregnancy occurs, stop and contact doctor.,Regular breast exams and mammograms are recommended.,May cause nausea; take with food or at bedtime.
"Concurrent use of bumetanide, a loop diuretic, and allopurinol, a xanthine oxidase inhibitor, may increase the risk of allopurinol hypersensitivity reactions, including Stevens-Johnson syndrome and acute gout flares. This interaction is thought to result from bumetanide-induced volume depletion and reduced renal clearance of oxypurinol, the active metabolite of allopurinol, leading to elevated serum oxypurinol levels and enhanced toxicity. Clinically, patients may present with rash, fever, eosinophilia, or acute gouty arthritis, particularly in those with renal impairment."
"The combination of allopurinol and captopril increases the risk of hypersensitivity reactions, including Stevens-Johnson syndrome and angioedema, due to a pharmacodynamic interaction that potentiates immune-mediated adverse effects. This is particularly concerning in patients with renal impairment, where both drugs may accumulate, and can lead to severe cutaneous adverse reactions or hematologic toxicities."
"Allopurinol inhibits xanthine oxidase, an enzyme involved in the catabolism of purine analogs. Tegafur is a prodrug of 5-fluorouracil and is metabolized via the same pathway. Coadministration of allopurinol may reduce the conversion of tegafur to its active metabolite, thereby decreasing the therapeutic efficacy of tegafur. This can lead to suboptimal antineoplastic effect and potential treatment failure."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOPURIN vs AMNESTROGEN, answered by our medical review team.
LOPURIN is a Xanthine oxidase inhibitor that works by LOPURIN is a brand name for allopurinol, a xanthine oxidase inhibitor. It reduces uric acid production by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.. AMNESTROGEN is a Estrogen that works by Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription and promoting development and maintenance of female reproductive tissues and secondary sex characteristics.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOPURIN and AMNESTROGEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOPURIN is: 200-600 mg orally once daily, typically starting at 300 mg/day and adjusting based on serum urate levels.. The standard adult dose of AMNESTROGEN is: 1 tablet (2.5 mg estradiol and 0.625 mg norgestimate) orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOPURIN and AMNESTROGEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOPURIN is classified as Category C. FDA Pregnancy Category D. First trimester: risk of congenital heart defects, cleft palate, and hypospadias based on animal studies and limited human data. Second and third trimeste. AMNESTROGEN is classified as Category C. First trimester: Increased risk of congenital anomalies including cardiovascular defects and neural tube defects. Second and third trimesters: Risk of urogenital tract abnormalitie. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.